Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP ...

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. The ...

Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and ...

Monroe Biomedical Research (MBR), a dedicated clinical trial site, is growing its footprint to enhance early-phase clinical trials and attract more research opportunities to North Carolina.

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...

CERo Therapeutics (CERO) announces the execution of an agreement with contract research organization CellCarta to manage translational assays ...

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the ...